BCBS files US antitrust claims against Teva over Copaxone
MLex Summary: Blue Cross Blue Shield filed a US complaint accusing Teva Pharmaceuticals of illegally delaying a generic competitor for multiple sclerosis treatment drug Copaxone. According to the complaint, Teva delayed...To view the full article, register now.
Already a subscriber? Click here to view full article